- Home
- LCTX vs HYB Comparison
LCTX vs HYB Comparison
Compare LCTX & HYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- HYB
- Stock Information
- Founded
- LCTX 1990
- HYB 1987
- Country
- LCTX United States
- HYB United States
- Employees
- LCTX N/A
- HYB N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- HYB Investment Managers
- Sector
- LCTX Health Care
- HYB Finance
- Exchange
- LCTX Nasdaq
- HYB Nasdaq
- Market Cap
- LCTX 110.2M
- HYB 191.2M
- IPO Year
- LCTX N/A
- HYB 1999
- Fundamental
- Price
- LCTX $0.55
- HYB $8.23
- Analyst Decision
- LCTX Strong Buy
- HYB
- Analyst Count
- LCTX 5
- HYB 0
- Target Price
- LCTX $4.80
- HYB N/A
- AVG Volume (30 Days)
- LCTX 2.9M
- HYB 39.6K
- Earning Date
- LCTX 03-06-2025
- HYB 01-01-0001
- Dividend Yield
- LCTX N/A
- HYB 6.67%
- EPS Growth
- LCTX N/A
- HYB N/A
- EPS
- LCTX N/A
- HYB N/A
- Revenue
- LCTX $8,719,000.00
- HYB N/A
- Revenue This Year
- LCTX N/A
- HYB N/A
- Revenue Next Year
- LCTX $41.15
- HYB N/A
- P/E Ratio
- LCTX N/A
- HYB N/A
- Revenue Growth
- LCTX N/A
- HYB N/A
- 52 Week Low
- LCTX $0.48
- HYB $6.23
- 52 Week High
- LCTX $1.61
- HYB $7.41
- Technical
- Relative Strength Index (RSI)
- LCTX 47.26
- HYB 51.78
- Support Level
- LCTX $0.51
- HYB $8.14
- Resistance Level
- LCTX $0.60
- HYB $8.29
- Average True Range (ATR)
- LCTX 0.04
- HYB 0.07
- MACD
- LCTX 0.01
- HYB 0.01
- Stochastic Oscillator
- LCTX 53.85
- HYB 66.67
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About HYB New America High Income Fund Inc. (The)
New America High Income Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide high current income while seeking to preserve stockholder capital by investing in a diversified portfolio of high-yield fixed-income securities. The Fund has a leveraged capital structure. The fund invests in fixed-maturity corporate debt securities that are rated less than the investment grade. Its portfolio of investment consists of investments in different sectors such as energy, financial, cable operators, healthcare, and others.